Navigation Links
Guidelines Seek to Boost Study of Critically Ill
Date:9/26/2007

Barriers around informed consent are impeding lifesaving research, experts say

WEDNESDAY, Sept. 26 (HealthDay News) -- Heart experts have released new recommendations designed to increase the number of studies of critically-ill or injured patients who are likely to die without treatment.

U.S. law requires that patients be fully informed of a study's risk and agree to participate before they're enrolled in medical studies. But informed consent can be impossible to obtain from unconscious patients in emergency situations.

The law does allow enrollment of patients who are unable to give informed consent if certain requirements are met, but many researchers say these requirements are hard to understand and implement, according to background information in the report.

The new recommendations, from an American Heart Association committee of cardiovascular care experts, are aimed at research scientists who conduct clinical trials of patients who aren't able to give informed consent due to the seriousness of their condition.

The effort may help reverse a major decline in studies on cardiac arrest, stroke and trauma, the report said.

This new report outlines different levels of additional risk associated with a clinical study and a clear set of rules and steps associated with the informed consent process.

"Separating the risk of the underlying critical condition of the patient from the additional risk of being in the study can be problematic. What often is missed is the additional risk of not doing an intervention -- for instance, not using a better compression device and instead providing subpar chest compressions to a patient in cardiac arrest," co-author Dr. Vinay Nadkarni, director of the center for resuscitation science at Children's Hospital of Philadelphia, said in a prepared statement.

The report is published in the journal Circulation.

More information


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. New CPR Guidelines issued by Heart Association
2. New guidelines for dealing with post traumatic stress disorder
3. New Guidelines Found To Benefit Cardiovascular Treatment
4. Healthy Feeding Guidelines for Children Ages 0 to 24 Months Issued
5. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
6. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
7. FDA To Set New Guidelines To Revise Drug Companies Marketing Tactics
8. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
9. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
10. Guidelines for treatment of juvenile idiopathic arthritis formulated
11. Guidelines For Better Management Of Obsessive-Compulsive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ill Seek Expanded Coverage, Affordability , , W...merican Federation of Government Employees (AFGE),...ratulates former Senate Majority Leader Tom Daschl...cretary of health and human services. Hearings beg...nt Obama,s selection of Daschle proves he is commi...
(Date:1/8/2009)...vaccine to provide complete protection against a m...d today in the Nature journal Gene Therapy . , ...tulinum , which produces toxins that cause paralys...eathing fail. Out of an average of 145 U.S. cases ..., intestines, unlike adults, are vulnerable to spo...
(Date:1/8/2009)...tCall/ -- Warner Chilcott Limited (Nasdaq: WCRX ... Annual JP Morgan Conference on Tuesday, January 1...ilcott will be Roger Boissonneault, President and ...ive Vice President and Chief Financial Officer. ,...t live for all interested parties at www.wcrx.com...
(Date:1/8/2009)... -- The owner and operator of two Miami medical cl...e program in connection with a $5.3 million HIV in...eral Matthew Friedrich of the Criminal Division an...n District of Florida announced today. , , Orla...9, to conspiracy to commit healthcare fraud before...
Breaking Medicine News(10 mins):Health News:Nose-spray vaccine against botulism effective in first tests 2Health News:Nose-spray vaccine against botulism effective in first tests 3Health News:Nose-spray vaccine against botulism effective in first tests 4Health News:Medical Clinic Owner Pleads Guilty to Role in $5.3 Million Medicare Fraud Scheme 2
...Ethnicity & Disease (Winter 2007), transcendental ...ring from congestive heart// failures. Scientists... a study on 23 African American who were admitted ...ailures. This group had a mix of men and women wit...
...sociation (AMSA) is hosting the 56th General Assem...dents’ Associations (IFMSA).// Medical students f... March 7 for the commencement of the biannual conf...such a premier event, held last year in Santiago, ...
...emotherapy for malignant skin cancer that has spre...ve //found, and patients have more serious side ef... combined. Malignant melanoma develops when cance...kin color, and is one of the most aggressive forms...
...rovisional safety rating until their safety and ef...opulation, experts have said in the latest Medical...xx and some other prescription medicines, which we...arketing, has shown that reliance on pre-marketing...
Other Medicine News:Health News:AMSA Hosts International Health Conference 2Health News:Immunotherapy Does Not Prolong Life When Skin Cancer Spreads 2Health News:Immunotherapy Does Not Prolong Life When Skin Cancer Spreads 3Health News:Time to Overhaul Australia's Medicines Safety Surveillance System 2
(Date:12/29/2008)...c. 29 The winner of the...ction was announced today by Dr. Peter G. Goldschm...nt Institute. , , The winner of the annual awa...ancer Center -- for its best practice " IND Regu...ides for 1) enhanced human subjects protection, 2)...
(Date:12/27/2008)...lif., Dec. 27 According to the lat...sed to consume modest doses of,resveratrol plus a...ided in 3,to 5 glasses of aged, red wine, rather ...www.newscom.com/cgi-bin/prnh/20080603/LATU039 ) ,...eratrol alone fails to prolong,the life of labora...
(Date:12/17/2008)... met in development and validation of non-animal a... Dec. 17 MatTek Corporation today ...ttee (ESAC) endorsed the scientific validity of th...ts November meeting. ESAC concluded that the Modi...bility for the prediction of skin irritating and n...
(Date:12/17/2008)... Complex of Its Kind; 80 Percent of Trauma Patient... A multi-disciplinary team of doct...ormed the first near-total face transplant in th... performed within the past two weeks, surgeons tra...d severe facial trauma -- essentially replacing he...
Breaking Medicine Technology:2008 Human Research Protection Award Recipients Announced 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3EpiDerm's Skin Irritation Test Fully Validated in European Union 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 3Non White Women More Prone to Breast Cancer Pain 6934 1Leading by Example 3A Blue Care Network of Michigan Shows How Employers Can Improve Employee Wellness 6932 1Leading by Example 3A Blue Care Network of Michigan Shows How Employers Can Improve Employee Wellness 6932 2Defining the Value of Medicine in an Evidence Based Healthcare Marketplace 6930 1Defining the Value of Medicine in an Evidence Based Healthcare Marketplace 6930 2Defining the Value of Medicine in an Evidence Based Healthcare Marketplace 6930 3GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 1GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 2GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 3GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 4GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 5GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 6GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 7GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 8GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 9GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 10GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 11GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 12GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 13GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 14GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 15GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 16GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 17GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 18GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 19GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 20GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 21GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 22GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 23GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 24GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 25GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 26GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 27GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 28GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 29GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 30GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 31GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 32GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 33GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 34GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 35GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 36GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 37GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 38GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 39GlaxoSmithKline Obtains Exclusive U S OTC Marketing Rights to MEVACOR 28R 29 28lovastatin 29 from Merck 26 Co Inc 6928 40
..., 2007-Pozen Inc. (NASDAQ: POZN),today announced ...of-of-concept study conducted during the fourth qu... 325mg of aspirin surrounded by,a 20mg coating of ...inhibitor. , The PA 325, 28 day study, involved tw...ubject was treated with either once a day,commerci...
... HILL, N.C., US, March 06, 2007,/PRNewswire/ -- AO...tibio, Inc. ("Lantibio") today announced positive ...e-blinded Phase II clinical,study of Moli1901, an ...F"). Moli1901 is being developed by AOP Orphan in,...eement with,Lantibio. The study, performed at mult...
Other Medicine Technology:Pozen Announces Positive Outcome for PA 325 2Pozen Announces Positive Outcome for PA 325 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 2AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 4
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
Medicine Products: